Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ANALYSIS OF RISK FACTORS OF 248 PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS
- CLONAL EVOLUTION STUDIED BY I-FISH IN B-CLL
- COMPARISON OF ALLOGENEIC STEM CELL TRANSPLANTATION AND IMATINIB FOR CHRONIC MYELOID LEUKEMIA: RESULTS FROM CAMELIA REGISTRY
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
- Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
- LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- LOW-DOSE FCR IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group
- LOW-DOSE FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINED WITH RITUXIMAB IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PROJECT Q-LITE OF CZECH CLL STUDY GROUP
- Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- PROGNOSTIC SIGNIFICANCE OF TELOMERE LENGTH, MOLECULAR CYTOGENETIC FINDINGS AND IMMUNOPHENOTYPIC FEATURES IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC LEUKEMIA
- SIGNIFICANCE OF ANEMIA IN PATIENTS WITH CML AT DIAGNOSIS AND DURING THE TREATMENT WITH IMATINIB OUTSIDE THE CLINICAL TRIALS: CAMELIA REGISTRY EXPERIENCE
- Sledování klonálního vývoje u B-CLL metodou I-FISH
- TELOMERE LENGTH EVALUATION IN PATIENTS WITH UNTREATED B-CHRONIC LYMPHOCYTIC LEUKEMIA - CORRELATION WITH OTHER MOLECULAR, CYTOGENETIC AND IMMUNOPHENOTYPIC FEATURES
- The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
